Can a diabetes drug duo protect your heart?

NCT ID NCT03878706

Recruiting now Disease control Sponsor: University of Athens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether combining two common diabetes drugs (GLP-1 agonists and SGLT2 inhibitors) can improve heart function and artery health in people with type 2 diabetes who are at high risk for heart problems. About 240 adults will be split into four groups, each receiving different treatments, and their heart health will be checked after 6 and 12 months. The goal is to find the best way to manage diabetes while protecting the heart.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS (TYPE 2)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

"Attikon" University General Hospital
RECRUITING

Athens, Attica, 12462, Greece

Contact